Document is current
Any future updates will be listed below
-
Authors
Axelrod, Christopher L https://orcid.org/0000-0002-1444-8557
King, William T https://orcid.org/0000-0003-2312-6207
Davuluri, Gangarao
Noland, Robert C
Hall, Jacob
Hull, Michaela
Dantas, Wagner S
Zunica, Elizabeth RM
Alexopoulos, Stephanie J
Hoehn, Kyle L
Langohr, Ingeborg
Stadler, Krisztian
Doyle, Haylee
Schmidt, Eva
Nieuwoudt, Stephan
Fitzgerald, Kelly
Pergola, Kathryn
Fujioka, Hisashi
Mey, Jacob T
Fealy, Ciaran
Mulya, Anny
Beyl, Robbie
Hoppel, Charles L
Kirwan, John P https://orcid.org/0000-0001-7321-9917
-
Funding
Funding for this research was provided by:
HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (DK108089)
HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (DK103860)
HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (DK115749)
HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (DK072476)
Department of Health|National Health and Medical Research Council (GNT1163903)
HHS|NIH|National Institute of General Medical Sciences (GM103528)
HHS|NIH|National Institute of General Medical Sciences (GM104940)
- License Information
-
More Information
Article History
Received: 29 January 2020
Revised: 15 May 2020
Accepted: 15 May 2020
First Online: 10 June 2020
Conflict of interest
: K.L.H. is an equity holder in Continuum Biosciences, a company that has commercial interest in mitochondrial uncouplers as therapeutics. All other authors declare no conflict of interest.
